Non mechanism-specific drugs

Intervention

1 paper1 finding

  • 1 lab in 1 country
  • Funder: European Society for Medical Oncology
  • 1 of 1 finding with company ties

Outcomes

1

Trial success

downin humans1OR 0.3

1 study
  1. Non mechanism-specific drugs decrease trial success in humans (OR 0.30, 95% CI 0.10-0.90).

    Reviewlower pretrial evidence

    Randomised phase III trials of cancer prevention drugs: a systematic review and prediction of trial success

    ESMO open8 Sep 2026

Latest

Nov 2025: 0Dec 2025: 0Jan 2026: 0Feb 2026: 0Mar 2026: 0Apr 2026: 0May 2026: 0Jun 2026: 0Jul 2026: 0Aug 2026: 0Sep 2026: 1Oct 2026: 01 in 12 months